Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis

Journal of Cystic Fibrosis

Volumn 11, Issue 1, 2012, Pages 8-13

  Waters, Valerie ^a   Atenafu, Eshetu G ^b   Salazar, Juliana Giraldo ^a   Lu, Annie ^a   Yau, Yvonne ^a   Matukas, Larissa ^c   Tullis, Elizabeth ^d   Ratjen, Felix ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Cystic fibrosis; Pulmonary exacerbation; Stenotrophomonas maltophilia

Indexed keywords

CLAVULANATE POTASSIUM PLUS TICARCILLIN; COTRIMOXAZOLE; DOXYCYCLINE; LEVOFLOXACIN;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; BURKHOLDERIA CEPACIA INFECTION; CHILD; CYSTIC FIBROSIS; DISEASE EXACERBATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SCHOOL CHILD; STENOTROPHOMONAS MALTOPHILIA INFECTION;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHRONIC DISEASE; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; RETROSPECTIVE STUDIES; STENOTROPHOMONAS MALTOPHILIA; YOUNG ADULT;

EID: 84855864416     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2011.07.008     Document Type: Article

References (20)

1. Waters V., Yau Y., Prasad S., Lu A., Atenafu E., Crandall I., et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 2011, 183:635-640.
2. Marchac V., Equi A., Le Bihan-Benjamin C., Hodson M., Bush A. Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients. Eur Respir J 2004, 23:98-102.
3. Talmaciu I., Varlotta L., Mortensen J., Schidlow D.V. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr Pulmonol 2000, 30:10-15.
4. Graff G.R., Burns J.L. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest 2002, 121:1754-1760.
5. Denton M., Todd N.J., Kerr K.G., Hawkey P.M., Littlewood J.M. Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples. J Clin Microbiol 1998, 36:1953-1958.
6. Sanders D.B., Bittner R.C., Rosenfeld M., Hoffman L.R., Redding G.J., Goss C.H. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010, 182:627-632.
7. Farrell P.M., Rosenstein B.J., White T.B., Accurso F.J., Castellani C., Cutting G.R., et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008, 53(Suppl. 1):4-14.
8. Collaco J.M., Green D.M., Cutting G.R., Naughton K.M., Mogayzel P.J. Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. Am J Respir Crit Care Med 2010, 182:1137-1143.
9. Denton M., Kerr K.G. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998, 11:57-80.
10. San Gabriel P., Zhou J., Tabibi S., Chen Y., Trauzzi M., Saiman L. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2004, 48:168-171.
11. 1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2010, 45:127-134.
12. VanDevanter D.R., O'Riordan M.A., Blumer J.L., Konstan M.W. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respir Res 2010, 11:137.
13. Marshall B.C. Pulmonary exacerbations in cystic fibrosis: it's time to be explicit!. Am J Respir Crit Care Med 2004, 169:781-782.
14. Liou T.G., Adler F.R., Fitzsimmons S.C., Cahill B.C., Hibbs J.R., Marshall B.C. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001, 153:345-352.
15. Konstan M.W., Morgan W.J., Butler S.M., Pasta D.J., Craib M.L., Silva S.J., et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007, 151:134-139.
16. Emerson J., Rosenfeld M., McNamara S., Ramsey B., Gibson R.L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002, 34:91-100.
17. Stevens D.A., Moss R.B., Kurup V.P., Knutsen A.P., Greenberger P., Judson M.A., et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003, 37(Suppl. 1):225-264.
18. 1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011, 46:393-400.
19. Gibson R.L., Burns J.L., Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003, 168:918-951.
20. Regelmann W.E., Elliott G.R., Warwick W.J., Clawson C.C. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990, 141:914-921.